A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance

Chemoresistance often leads to the failure of breast cancer treatment. MicroRNAs (miRNAs) play an important role in the progression and chemoresistance of cancer. However, because of the complexity of the mechanisms of chemoresistance and the specificity of miRNA regulation in different cell types, the function of miR-20a in breast cancer chemoresistance is still unclear. Here, by using miRNA microarray and high-content screening techniques, we found that miR-20a/b were significantly downregulated in breast cancer tissues compared with normal breast tissues, and low miR-20a/b expression was correlated with poor survival in breast cancer patients. Ectopic overexpression of miR-20a sensitized breast cancer cells to a broad spectrum of chemotherapy drugs and suppress their proliferation both in vitro and in vivo. Further study demonstrated that miR-20a directly targeted the 3'untranslated region of MAPK1, and thus downregulated the expression of P-gp and c-Myc by inhibiting the MAPK/ERK signaling pathway, whereas c-Myc can bind to the promoter region of the miR-20a gene to promote the expression of miR-20a. Together, our study identified a novel miR-20a/MAPK1/c-Myc feedback loop that regulates breast cancer growth and chemoresistance. These findings suggest that miR-20a synergizing with anticancer drugs will be a promising treatment strategy, especially for chemoresistant patients.

[1]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[2]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[3]  Hongyang Wang,et al.  MiR-20a triggers metastasis of gallbladder carcinoma. , 2013, Journal of hepatology.

[4]  J. McCubrey,et al.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention , 2003, Leukemia.

[5]  Fei Ren,et al.  MiR-20a Promotes Cervical Cancer Proliferation and Metastasis In Vitro and In Vivo , 2015, PloS one.

[6]  M. Chamberlain,et al.  Cross-talk between signalling pathways and the multidrug resistant protein MDR-1 , 2001, British Journal of Cancer.

[7]  Wei Xiong,et al.  MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* , 2010, The Journal of Biological Chemistry.

[8]  Dah-Shyong Yu,et al.  Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. , 2005, The Journal of urology.

[9]  S. Zhong,et al.  Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[10]  Scott M Lippman,et al.  Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[11]  Zongguang Zhou,et al.  MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4 , 2016, Oncotarget.

[12]  F. Aoudjit,et al.  Collagen/β1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner , 2012, Molecular biology of the cell.

[13]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[14]  B. Jiang,et al.  Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein , 2014, Oncotarget.

[15]  Hui Zhou,et al.  Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. , 2014, Cancer research.

[16]  Daniel Birnbaum,et al.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.

[17]  B. Song,et al.  Suppression of CX43 expression by miR-20a in the progression of human prostate cancer , 2012, Cancer biology & therapy.

[18]  V. Eusebi,et al.  Rare (new) entities of the breast and medullary carcinoma. , 2009, Pathology.

[19]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.

[20]  Li Lin,et al.  Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. , 2011, Cancer cell.

[21]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[22]  Xin Li,et al.  miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. , 2011, Acta biochimica et biophysica Sinica.

[23]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[24]  W. Fan,et al.  Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells. , 2013, Cancer letters.

[25]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[26]  Jun Yin,et al.  miRNA 17 Family Regulates Cisplatin-Resistant and Metastasis by Targeting TGFbetaR2 in NSCLC , 2014, PloS one.

[27]  Wenlin Huang,et al.  MicroRNA-20a overexpression inhibited proliferation and metastasis of pancreatic carcinoma cells. , 2010, Human gene therapy.

[28]  J. Nevins,et al.  Ras enhances Myc protein stability. , 1999, Molecular cell.

[29]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[30]  H. Qian,et al.  miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation. , 2013, European journal of cancer.

[31]  G. Shan,et al.  CCAR1 5′ UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance , 2016, Cell Research.

[32]  Y. Sugimoto,et al.  Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein , 2007, Molecular Cancer Therapeutics.

[33]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[34]  Zuoren Yu,et al.  miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1 , 2014, Oncotarget.

[35]  E. Song,et al.  Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. , 2014, Cancer research.

[36]  M. Kudo,et al.  Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[37]  W. Fan,et al.  Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy. , 2014, Cancer letters.

[38]  Stephen Safe,et al.  IDENTIFICATION OF ONCOGENIC MicroRNA-17-92/ZBTB4/SPECIFICITY PROTEIN AXIS IN BREAST CANCER , 2011, Oncogene.

[39]  Jie Zhou,et al.  microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling , 2010, Proceedings of the National Academy of Sciences.

[40]  Zhihua Liu,et al.  MicroRNA-17/20a impedes migration and invasion via TGF-β/ITGB6 pathway in esophageal squamous cell carcinoma. , 2016, American journal of cancer research.

[41]  V. Ambros The functions of animal microRNAs , 2004, Nature.

[42]  Shengyao Wang,et al.  Grape Seed Procyanidin Reversal of P-glycoprotein Associated Multi-Drug Resistance via Down-regulation of NF-κB and MAPK/ERK Mediated YB-1 Activity in A2780/T Cells , 2013, PloS one.

[43]  S. Cai,et al.  MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene , 2016, Cancer Cell International.

[44]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[45]  Terry Hyslop,et al.  A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation , 2008, The Journal of cell biology.

[46]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[47]  D. Liao,et al.  c-Myc in breast cancer. , 2000, Endocrine-related cancer.

[48]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[49]  F. Aoudjit,et al.  Collagen / beta 1 integrin signaling upregulates the ABCC 1 / MRP-1 transporter in an ERK / MAPK-dependent manner , 2012 .

[50]  Tara L. Naylor,et al.  microRNAs exhibit high frequency genomic alterations in human cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Vincent-Salomon,et al.  Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity , 2007, Breast Cancer Research.

[52]  E. Kleinerman,et al.  miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. , 2012, Cancer research.

[53]  Vladimir I. Vladimirov,et al.  MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders , 2010, Schizophrenia Research.

[54]  T. Jin,et al.  MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression , 2014, Oncotarget.

[55]  M. Kuo,et al.  MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. , 2013, Oral oncology.

[56]  Yixue Li,et al.  miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression , 2015, Cell Research.

[57]  Ying Tang,et al.  Repression of the miR‐17‐92 cluster by p53 has an important function in hypoxia‐induced apoptosis , 2009, The EMBO journal.